ClinGen *CDH1* Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines Version 3

This version specified for the following genes: *CDH1*

Expert Panel Page: https://www.clinicalgenome.org/affiliation/50014

Gene	Disease (MONDO ID)	Clinically significant transcript
CDH1	hereditary diffuse gastric cancer (MONDO:0007648)	NM_004360.5

Summary of changes in Version 3:

Major changes:

(1) Adoption of the 2020 updated clinical practice guidelines (PMID: 32758476), as it applies to the HDGC phenotype criteria (attached below), for PS2, PS4, PM6, and PP1.

(2) Development of a decision tree to specify *CDH1* PVS1 rules (attached).

(3) Integration of splice site specific recommendations to determine the strength of PVS1 criterion.

(4) Specification of PM5_supporting to nonsense and frameshift variants that are predicted and/or proven to undergo nonsense-mediated decay (NMD), or to splicing variants in acceptor/donor sites that have at least one other variant meeting P/LP at the same site. (Validation Table attached).

(5) Downgrade of PM2 to supporting strength.

(6) Removal of PS1 as an applicable evidence code.

(7) Removal of the conservation requirement from BP7 and expansion of BP7 to intronic variants at or within +7 to -21 locations.

(8) Use of the Bayesian point system in curations with conflicting evidence that otherwise result in a classification of VUS.

(9) Clarification on the usage of PS4, PM2, PM4, PP1, BS2, BS3, BP2, BP4, and BP5.

Related publication(s): PMID 30311375   **Date Approved: 09/20/2021**

This document is archived and versioned on ClinGen's website. Please check https://www.clinicalgenome.org/affiliation/50014/docs/assertion-criteria for the most recent version.

ClinGen_CDH1_ACMG_Specifications_v3

ClinGen *CDH1* Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines Version 3

This version specified for the following genes: *CDH1*

Expert Panel Page: https://www.clinicalgenome.org/affiliation/50014

Minor changes:

(1) Updating PP3 and BP4 to include SpliceAI as a recommended splicing predictor.

(2) Specifying a subpopulation minimum allele threshold of 2,000 for the application of BA1 and BS1.

(3) Specifying a mean coverage of at least 30X for application of BA1, BS1, and PM2.

(4) Uniform the language of not used codes as ''Not applicable for *CDH1*'' and some typo corrections.

ACMG/AMP Criteria Codes	Original ACMG/AMP Rule Summary	*CDH1* Rule Specifications					
		Stand Alone	**Very Strong**	**Strong**	**Moderate**	**Supporting**	**Comments**
PVS1	Null variant in a gene where LoF is a known mechanism of disease	---	Per modified *CDH1* PVS1 decision tree	Per modified *CDH1* PVS1 decision tree Other *CDH1* caveats: - Use PVS1_Strong as the default strength of evidence for canonical splice site variants and follow the site-specific recommendations in the splicing table.	Per modified *CDH1* PVS1 decision tree Other *CDH1* caveats: - G to non-G variants disrupting the last nucleotide of an exon - Canonical splice sites predicted or demonstrated experimentally to result in in-frame partial	N/A	RNA analysis is recommended for splicing alterations, and if the RNA evidence does not support the prediction, the strength should be updated

				- CDH1 Exonic deletions or tandem duplications of in-frame exons (exon 4,5,8,9,12,13,15)	skipping/insertion (e.g., Exon 3 donor site)		
PS1	Same amino acid change as a previously established pathogenic variant regardless of nucleotide change	---	---	---	---	---	Not applicable for *CDH1*
PS2	*De novo* (both maternity and paternity confirmed) in a patient with the disease and no family history	---	>Two patients meet the HDGC individual phenotype criteria w/ parental confirmation	One patient meets the HDGC individual phenotype criteria w/ parental confirmation	---	---	Use ClinGen's *de novo* point system for a highly specific phenotype (see Table S2)
PS3	Well-established *in vitro* or *in vivo* functional studies supportive of a damaging effect on the gene or gene product	---	---	RNA assay demonstrating abnormal out-of-frame transcripts	---	RNA assay demonstrating abnormal in-frame transcripts	This rule can only be applied to demonstrate splicing defects.
PS4	Prevalence of variant in affected individuals is significantly increased compared to controls	---	>Sixteen families meet HDGC criteria	Four - Fifteen families meet HDGC criteria	Two or three families meet HDGC criteria	One family meets HDGC criteria	Use the 2020 updated clinical practice guidelines (PMID: 32758476) as the HDGC phenotype criteria. PS4 <u>cannot</u> be applied to variants that meet BS1 or BA1, or to variants in which less than 30% of

This document is archived and versioned on ClinGen's website. Please check https://www.clinicalgenome.org/affiliation/50014/docs/assertion-criteria for the most recent version.

ClinGen_CDH1_ACMG_Specifications_v3

ClinGen *CDH1* Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines Version 3

This version specified for the following genes: *CDH1*

Expert Panel Page: https://www.clinicalgenome.org/affiliation/50014

							reported individuals meet HDGC criteria.
PM1	Located in a mutational hot spot and/or critical and well-established functional domain without benign variation	---	---	---	---	---	Not applicable for *CDH1*
PM2	Absent in population databases	---	---	---	≤ One out of 100,000 alleles in gnomAD cohort; if present in ≥2 individuals within a subpopulation, must be present in ≤ One out of 50,000 alleles	---	Use gnomAD to determine allele frequency. The mean coverage of *CDH1* in the population database used should be at least 30x.
PM3	For recessive disorders, detected in trans with a pathogenic variant	---	---	---	---	---	Not applicable for *CDH1*
PM4	Protein length changes as a result of in-frame deletions/insertions in a nonrepeat region or stop-loss variants	---	---	---	Only apply to stop-loss variants Variant example: *CDH1* c.2647T>C (p.Ter883Glnext*29)	---	PM4 is not applied to small in-frame indels because the impact of amino acid level changes of *CDH1* variants is inconclusive.
PM5	Novel missense change at amino acid residue where a different missense variant is pathogenic	---	---	---	---	PM5_supporting is applicable to nonsense and frameshift variants that are predicted/proved to undergo NMD.	The nonsense or frameshift variant must not impact splicing based on RNA assay or splicing predictions.

ClinGen_CDH1_ACMG_Specifications_v3

ClinGen *CDH1* Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines Version 3

This version specified for the following genes: *CDH1*

Expert Panel Page: https://www.clinicalgenome.org/affiliation/50014

							Site-specific recommendations for the application of PM5_Supporting for canonical splicing variants are provided in the splicing table.	
PM6	Assumed *de novo*, but w/o confirmation of paternity and maternity	---	>Four patients meet the HDGC individual phenotype criteria w/o parental confirmation	>Two patients meet the HDGC individual phenotype criteria w/o parental confirmation	One patient meets the HDGC individual phenotype criteria w/o parental confirmation	---		Use ClinGen's *de novo* point system for a highly specific phenotype (See Table S2)
PP1	Cosegregation in multiple affected family members in a gene definitively known to cause the disease	---	---	>Seven informative meioses across >2 families	Five-six informative meioses across >1 family	Three-four informative meioses across >1 family		Based strength of rule code on number of meioses across one or more families
PP2	Missense variant in a gene with a low rate of benign missense variation & where missense variants are a common mechanism of disease	---	---	---	---	---		Not applicable for *CDH1*
PP3	Multiple lines of computational evidence support a deleterious	---	---	---	Variants affecting the same splice site as a well-characterized	At least three *in silico* splicing predictors in		PP3 cannot be applied for canonical splice sites. PP3 code also does not apply

This document is archived and versioned on ClinGen's website. Please check https://www.clinicalgenome.org/affiliation/50014/docs/assertion-criteria for the most recent version.

ClinGen_CDH1_ACMG_Specifications_v3

	effect on the gene or gene product				variant with similar or worse *in silico*/ RNA predictions	agreement (SpliceAI, MaxEntScan, SSF, GeneSplicer, HSF, TraP, varSEAK)	to the last nucleotide of exon 3 (c.387G). Do <u>not</u> use protein-based computational prediction models for missense variants.
PP4	Patient's phenotype or family history is highly specific for a disease with a single genetic etiology	---	---	---	---	---	Not applicable for *CDH1*
PP5	Reputable source recently reports variant as pathogenic	---	---	---	---	---	Not applicable for *CDH1*
BA1	Allele frequency is greater than expected for disorder	MAF cutoff of 0.2%	---	---	---	---	99.99% CI; subpopulation must ≥ 2,000 alleles and have a minimum of five variant alleles present
BS1	Allele frequency is greater than expected for disorder	MAF cutoff of 0.1%	---	---	---	---	99.99% CI; subpopulation must ≥ 2,000 alleles and have a minimum of five variant alleles present. We allow a variant to reach a likely benign classification based on BS1 alone.
BS2	Observed in a healthy adult individual for a	---	---	Variant seen in >10 individuals w/o GC, DGC,	---	Variant seen in >3 individuals w/o	We allow a variant to reach a likely benign

This document is archived and versioned on ClinGen's website. Please check https://www.clinicalgenome.org/affiliation/50014/docs/assertion-criteria for the most recent version.

ClinGen_CDH1_ACMG_Specifications_v3

		dominant disorder with full penetrance expected at an early age			gSRC tumors, or LBC & whose families do not suggest HDGC		GC, DGC, SRC tumors, or LBC & whose families do not suggest HDGC	classification based on BS2 alone. BS2 <u>cannot</u> be applied to variants in which more than 30% of reported individuals meet HDGC criteria.
BS3	Well-established *in vitro* or *in vivo* functional studies show no damaging effect on protein function or splicing	---	---	Functional RNA studies demonstrating no impact on transcript composition	---	---	This rule can <u>only</u> be used to demonstrate lack of splicing and can <u>only</u> be applied to Synonymous, Intronic or Non-coding variants. BS3 may be downgraded based on quality of data	
BS4	Lack of segregation in affected members of a family	---	---	Per original ACMG/AMP guidelines	---	---	Beware of the presence of phenocopies (e.g., breast cancer) that can mimic lack of segregation. Also, families may have more than one pathogenic variant contributing to another AD disorder	
BP1	Missense variant in a gene for which primarily truncating variants are known to cause disease	---	---	---	---	---	Not applicable for *CDH1*	

BP2	Observed in a healthy homozygous individual, or in *trans* with a pathogenic variant for a fully penetrant dominant gene/disorder or observed in *cis* with a pathogenic variant	---	---	Variant observed *in trans* w/known pathogenic variant (phase confirmed) **OR** observed in the homozygous state in individual w/o personal &/or family history of DGC, LBC, or SRC tumors	---	Variant is observed *in cis* (or phase is unknown) w/ a pathogenic variant **OR** observed in the homozygous state in gnomAD	Evidence code is dependent on the strength of data. Take consideration of the quality of sequencing data when applying code.
BP3	In-frame deletions/insertions in a repetitive region without a known function	---	---	---	---	---	Not applicable for *CDH1*
BP4	Multiple lines of computational evidence suggest no impact on gene/gene product	---	---	---	---	Splicing predictions only. At least three *in silico* splicing predictors in agreement (SpliceAI, MaxEntScan, SSF, GeneSplicer, HSF, TraP, varSEAK)	Do not use protein based computational prediction models and BP4 is not applicable for missense variants.

Related publication(s): PMID 30311375   **Date Approved: 09/20/2021**

This document is archived and versioned on ClinGen's website. Please check https://www.clinicalgenome.org/affiliation/50014/docs/assertion-criteria for the most recent version.

ClinGen_CDH1_ACMG_Specifications_v3

BP5	Variant found in a case with an alternate molecular basis for disease	---	---	---	---	Per original ACMG/AMP guidelines	This applies if a P/LP variant is identified in an alternate gene known to cause HDGC (currently only *CTNNA1*)
BP6	Reputable source recently reports variant as benign	---	---	---	---	---	Not applicable for *CDH1*
BP7	Synonymous variant which splicing prediction algorithms predict no impact to the splice consensus sequence nor the creation of a new splice site & the nucleotide is not highly conserved.	---	---	---	---	Synonymous and intronic variants at or beyond +7 to -21 locations.	Note the *CDH1* rule specification does <u>not</u> require a conservation prediction. We allow use of BP7 with BP4, as appropriate, to classify variants meeting both criteria as likely benign.

This document is archived and versioned on ClinGen's website. Please check https://www.clinicalgenome.org/affiliation/50014/docs/assertion-criteria for the most recent version.

ClinGen_CDH1_ACMG_Specifications_v3

ClinGen *CDH1* Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines Version 3

This version specified for the following genes: *CDH1*

Expert Panel Page: https://www.clinicalgenome.org/affiliation/50014

PVS1 decision tree


ClinGen_CDH1_ACMG_Specifications_v3

ClinGen *CDH1* Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines Version 3

This version specified for the following genes: *CDH1*

Expert Panel Page: https://www.clinicalgenome.org/affiliation/50014

Splicing Table

Exon	GT-AG 1,2 Splice site	Location	Prediction if exon skipping	RNA assay	Canonical splice site variants curated	Recommended PVS1 strength and the application of PM5_Supporting criterion
Exon 1	Donor	c.48	Likely cryptic site		LP: c.48+1G>A	**PVS1_Strong+PM5_Supporting**
Exon 2	Acceptor	c.49	frameshift	frameshift	P: c.49-2A>G*	**PVS1_Strong+PM5_Supporting**
Exon 2	Donor	c.163	frameshift			**PVS1_Strong**
Exon 3	Acceptor	c.164	frameshift			**PVS1_Strong**
Exon 3	Donor	c.387	frameshift	in-frame transcripts	VUS: c.387+1G>A*	**PVS1_Moderate**
Exon 4	Acceptor	c.388	In-frame deletion (aa130-177)			**PVS1_Strong**
Exon 4	Donor	c.531	In-frame deletion (aa130-177)		LP: c.531+1G>A	**PVS1_Strong+PM5_Supporting**
Exon 5	Acceptor	c.532	In-frame deletion (aa178-229)		LP: c.532-1G>C	**PVS1_Strong+PM5_Supporting**
Exon 5	Donor	c.687	In-frame deletion (aa178-229)		LP: c.687+1G>A; c.687+2T>C	**PVS1_Strong+PM5_Supporting**

This document is archived and versioned on ClinGen's website. Please check https://www.clinicalgenome.org/affiliation/50014/docs/assertion-criteria for the most recent version.

ClinGen_CDH1_ACMG_Specifications_v3

ClinGen *CDH1* Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines Version 3

This version specified for the following genes: *CDH1*

Expert Panel Page: https://www.clinicalgenome.org/affiliation/50014

Exon 6	**Acceptor**	**c.688**	**frameshift**			**PVS1_Strong**
	Donor	**c.832**			P: c.832+1G>T LP: c.832+1G>A	**PVS1_Strong+PM5_Supporting**
Exon 7	**Acceptor**	**c.833**	**frameshift**	**frameshift**	P: c.833-2A>G*	**PVS1_Strong+PM5_Supporting**
	Donor	**c.1008**		**frameshift with cryptic site**	LP: c.1008+2T>C; c.1008G>A*; c.1008G>T*	**PVS1_Strong+PM5_Supporting**
Exon 8	**Acceptor**	**c.1009**	**In-frame deletion (aa337-379)**			**PVS1_Strong**
	Donor	**c.1137**		**frameshift with cryptic site**	P: c.1137+1delG; c.1137G>A* LP: c.1137+1G>A; c.1137+2T>C	**PVS1_Strong+PM5_Supporting**
Exon 9	**Acceptor**	**c.1138**	**In-frame deletion (aa380-440)**			**PVS1_Strong**
	Donor	**c.1320**		**in-frame deletion (exon 9 skipping)**	LP: c.1320+1G>C*	**PVS1_Strong+PM5_Supporting**
Exon 10	**Acceptor**	**c.1321**	**frameshift**			**PVS1_Strong**
	Donor	**c.1565**			P: c.1565+1G>C; c.1565+1G>A; c.1565+1G>T; c.1565+2dupT LP: c.1565+1delG	**PVS1_Strong+PM5_Supporting**

This document is archived and versioned on ClinGen's website. Please check https://www.clinicalgenome.org/affiliation/50014/docs/assertion-criteria for the most recent version.

ClinGen_CDH1_ACMG_Specifications_v3

ClinGen *CDH1* Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines Version 3

This version specified for the following genes: *CDH1*

Expert Panel Page: https://www.clinicalgenome.org/affiliation/50014

Exon 11	**Acceptor**	**c.1566**	**frameshift**	**predicted in-frame insertion with potential rescue transcript**	**VUS: c.1566-1G>C; c.1566-2A>G**	**PVS1_Moderate**
	Donor	**c.1711**			**LP: c.1711+1G>C; c.1711+1G>A; c.1711+2_1711+7delTAAGGG**	**PVS1_Strong+PM5_Supporting**
Exon 12	**Acceptor**	**c.1712**	**In-frame deletion (aa571-646)**	**in-frame deletion (c.1712_1720del9)**	**VUS: c.1712-2A>C***	**PVS1_Moderate**
	Donor	**c.1936**				**PVS1_Strong**
Exon 13	**Acceptor**	**c.1937**	**In-frame deletion (aa646-722)**			**PVS1_Strong**
	Donor	**c.2164**			**VUS: c.2164+2T>C** **VUS: c.2164+2dup (this variant actually affects +3 location)**	**PVS1_Strong**
Exon 14	**Acceptor**	**c.2165**	**frameshift**		**LP: c.2165-1G>C**	**PVS1_Strong+PM5_Supporting**
	Donor	**c.2295**				**PVS1_Strong**

This document is archived and versioned on ClinGen's website. Please check https://www.clinicalgenome.org/affiliation/50014/docs/assertion-criteria for the most recent version.

ClinGen_CDH1_ACMG_Specifications_v3

ClinGen *CDH1* Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines Version 3

This version specified for the following genes: *CDH1*

Expert Panel Page: https://www.clinicalgenome.org/affiliation/50014

Exon 15	**Acceptor**	**c.2296**	**In-frame deletion (aa766-813)**		**LP: c.2296-1G>A; c.2296-2A>G**	**PVS1_Strong+PM5_Supporting**
	Donor	**c.2439**				**PVS1_Strong**
Exon 16	**Acceptor**	**c.2440**	**Likely cryptic site**	**abnormal splicing**	**LP: c.2440-2A>G***	**PVS1_Strong+PM5_Supporting**

* RNA functional assay performed.

ClinGen *CDH1* Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines Version 3

This version specified for the following genes: *CDH1*

Expert Panel Page: https://www.clinicalgenome.org/affiliation/50014

Application of PM5_supporting to nonsense/frameshift variants that are predicted/proved to undergo NMD

Exon	Location	No. of nonsense/frameshift curated (N=113) before applying PM5_Supporting
Exon 1	c.1-c.48	P (1): c.26C>A (p.Ser9Ter) LP (2): c.11G>A (p.Trp4Ter); c.12G>A (p.Trp4Ter)
Exon 2	c.49-c.163	P (4): c.59G>A (p.Trp20Ter); c.60G>A (p.Trp20Ter); c.70G>T (p.Glu24Ter); c.124_126delCCCinsT (p.Pro42Serfs) LP (1): c.76G>T (p.Glu26Ter)
Exon 3	c.164-c.387	P (8): c.187C>T (p.Arg63Ter); c.208dup (p.Ser70Phefs); c.220C>T (p.Arg74Ter); c.283C>T (p.Gln95Ter); c.308G>A (p.Trp103Ter); c.360dup (p.His121fs); c.377del (p.Pro126Argfs); c.382delC (p.His128Ilefs) LP (5): c.202delT (p.Tyr68Ilefs); c.261delG (p.Arg87Serfs); c.315delC (p.Thr106Profs); c.337A>T (p.Lys113Ter); c.369_375CCGCCCC[3] (p.His128fs)
Exon 4	c.388-c.531	P (6): c.454_460delCAGAAGA (p.Gln152Glufs); c.480_486delinsAGAATA (p.Ile161fs); c.489C>A (p.Cys163Ter); c.521dupA (p.Asn174Lysfs); c.504delA (p.Gly169Alafs); c.529C>T (p.Gln177Ter) LP (7): c.436_437TC[1] (p.Pro147fs); c.454_460dup (p.Arg154Thrfs); c.455_465delAGAAGAGAGAC (p.Gln152Leufs); c.457_460delAAGA (p.Lys153Glufs); c.457A>T (p.Lys153Ter); c.467G>A (p.Trp156Ter); c.468G>A (p.Trp156Ter)
Exon 5	c.532-c.687	P (2): c.603delT (p.Val202Leufs); c.656del (p.Pro219fs) LP (1): c.594_595insT (p.Thr199fs)
Exon 6	c.688-c.832	P (1): c.720del (p.Asn240fs) LP (4): c.692_693TC[2] (p.His233fs); c.707C>A (p.Ser236Ter); c.781G>T (p.Glu261Ter); c.793G>T (p.Glu265Ter)
Exon 7	c.833-c.1008	P (2): c.940A>T (p.Lys314Ter); c.1003C>T (p.Arg335Ter)
Exon 8	c.1009-c.1137	P (7): c.1009_1010delAG (p.Ser337Phefs); c.1023T>G (p.Tyr341Ter); c.1051C>T (p.Gln351Ter); c.1064delT (p.Leu355Terfs); c.1085delT (p.Val362Glyfs); c.1107del (p.Asn369Lysfs); c.1131del (p.Thr378fs)

This document is archived and versioned on ClinGen's website. Please check https://www.clinicalgenome.org/affiliation/50014/docs/assertion-criteria for the most recent version.

ClinGen_CDH1_ACMG_Specifications_v3

ClinGen *CDH1* Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines Version 3

This version specified for the following genes: *CDH1*

Expert Panel Page: https://www.clinicalgenome.org/affiliation/50014

		LP (1): c.1031_1032dup (p.Val345fs)
Exon 9	**c.1138-c.1320**	P (2): c.1147C>T (p.Gln383Ter); c.1235_1236TA[3] (p.Ile415fs) LP (2): c.1170del (p.Asn390fs): c.1312del (p.Thr438fs)

Exon 10	**c.1321-c.1565**	P (4): c.1408del (p.Thr470fs); c.1476_1477delAG (p.Arg492Serfs); c.1488_1494delCGAGGAC (p.Glu497Leufs);
		      c.1531C>T (p.Gln511Ter)
		LP (7): c.1341del (p.Lys447fs); c.1354_1357del (p.Leu452fs); c.1390del (p.Val464fs); c.1443del (p.Asn481fs);
		      c.1460_1461del (p.Val487Alafs); c.1480G>T (p.Glu494Ter); c.1505delG (p.Gly502Alafs)

Exon 11	**c.1566-c.1711**	P (4): c.1578G>A (p.Trp526Ter); c.1587dup (p.Ala530fs); c.1590dup (p.Asn531fs); c.1612delG (p.Asp538Thrfs) LP (3): c.1569T>A (p.Tyr523Ter); c.1636delG (p.Ala546Leufs); c.1679dup (p.Tyr561Valfs)
Exon 12	**c.1712-c.1936**	P (6): c.1733dup (p.Gly579fs); c.1779dup (p.Ile594fs); c.1792C>T (p.Arg598Ter); c.1895_1896delAC (p.His632Argfs); c.1913G>A (p.Trp638Ter); c.1921C>T (p.Gln641Ter) LP (2): c.1746dup (p.Leu583Alafs); c.1917_1918del (p.Ile640fs)

Exon 13	**c.1937-c.2164**	P (5): c.1979dup (p.Gly661_Asp662insTer); c.1999del (p.Leu667fs); c.2062_2063TG[1] (p.Cys688_Glu689delinsTer);
		      c.2095C>T (p.Gln699Ter); c.2100del (p.Val701Serfs);
		LP (8): c.1942G>T (p.Glu648Ter); c.1948_1949del (p.Ile650HisfsTer12); c.1948_1949dup (p.Ile651Serfs);
		      c.1993del (p.Ile665Serfs); c.2029dup (p.Gln677Profs); c.2076_2077del (p.Gly693ArgfsTer3); c.2104G>T (p.Glu702Ter);
		      c.2144delG (p.Gly715Glufs)

Exon 14	**c.2165-c.2295**	P (4): c.2265T>A (p.Tyr755Ter); c.2276delG (p.Gly759Glufs); c.2287G>T (p.Glu763Ter); c.2293C>T (p.Gln765Ter) LP (1): c.2272G>T (p.Glu758Ter)
Exon 15	**c.2296-c.2439**	P (2): c.2398delC (p.Arg800Alafs); c.2430delT (p.Phe810Leufs) LP (3): c.2311C>T (p.Gln771Ter); c.2324delG (p.Gly775Alafs); c.2386dup (p.Arg796Profs)
Exon 16	**c.2440-c.2649**	P (1): c.2506G>T (p.Glu836Ter)

This document is archived and versioned on ClinGen's website. Please check https://www.clinicalgenome.org/affiliation/50014/docs/assertion-criteria for the most recent version.

ClinGen_CDH1_ACMG_Specifications_v3

		LP (2): c.2446A>T (p.Lys816Ter); c.2490dup (p.Leu831Alafs)
		VUS (5): c.2505_2506dup (p.Glu836fs); c.2526delT, p.(Ala843Leufs); c.2547_2548insA (p.Ser850fs);
		c.2549_2550delCC (p.Ser850Phefs); c.2594G>A (p.Trp865Ter)

2020 hereditary diffuse gastric cancer (HDGC) genetic testing criteria

Family criteria, where family members are first-degree or second-degree blood relatives of each other:	
1	≥2 cases of gastric cancer in family regardless of age, with at least one DGC
2	≥1 case of DGC at any age in family, and ≥1 case of LBC at age <70 years, in different family members
3	≥2 cases of LBC in family members <50 years of age
Individual criteria:	
4	DGC at age <50 years
5	DGC at any age in individuals of Maori ethnicity
6	DGC at any age in individuals with a personal or family history (first-degree relative) of cleft lip or cleft palate
7	History of DGC and LBC, both diagnosed <70 years
8	Bilateral LBC, diagnosed at age <70 years
9	Gastric in situ signet ring cells (SRC) or pagetoid spread of SRCs in individuals <50 years of age

Related publication(s): PMID 30311375   **Date Approved: 09/20/2021**

This document is archived and versioned on ClinGen's website. Please check https://www.clinicalgenome.org/affiliation/50014/docs/assertion-criteria for the most recent version.

ClinGen_CDH1_ACMG_Specifications_v3